Please login to the form below
Hetlioz
This page shows the latest Hetlioz news and features for those working in and with pharma, biotech and healthcare.
BMS' Opdivo backed as melanoma therapy in EU
Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -
Latest news
-
FDA approves sleep disorder drug for blind people
Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock. ... This means Vanda was able to take advantage of a number of development incentives due to the orphan-drug designation for Hetlioz.
-
FDA panel backs sleep pattern drug for blind
Vanda’s Hetlioz intended to improve circadian rhythms in people who cannot see. ... A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Featured jobs
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
- Global Business Development Director – Health Education
-
excellent commission
-
Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager / Account Director
-
Competative
-
Senior Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
- NICE gives Lilly’s Verzenios chance to compete with rivals
- J&J’s Erleada cleared for early prostate cancer in Europe
- New faces at Lucid, 90Ten and Page & Page
- 90TEN gets 2019 off to a strong start with four new hires
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
Quick links
Infographics
